Robert L. Zerbe co-founded and is retired chief executive officer of QuatRx Pharmaceuticals Company, a venture-backed drug development company that developed the recently launched product for postmenopausal dyspareunia, Osphena®. Prior to QuatRx, Dr. Zerbe held several senior executive management positions with major pharmaceutical companies including Eli Lilly and Pfizer (formerly Parke-Davis). During his tenure at Eli Lilly, Dr. Zerbe’s clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In this capacity he led the clinical development programs for a number of key products, including Neurontin® and Lipitor®. Dr. Zerbe received his M.D. from the Indiana University School of Medicine, and has completed post-doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. He currently serves as Chairman of the Board of Vericel Corporation, a public specialty biologics company developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions.